FDA Approves First Alzheimer's Blood Test for Ages 40+

For the first time, Americans showing early signs of memory loss can get tested for Alzheimer's disease with a simple blood draw instead of a painful spinal tap or costly brain scan.

The FDA just cleared PrecivityAD2, a blood test that can detect Alzheimer's in patients as young as 40. It's the first test of its kind approved for people this young, marking a major shift in how doctors diagnose the disease.

The test works by measuring specific proteins in the blood that signal Alzheimer's is developing in the brain. In a study of over 1,100 people, it correctly identified nearly 98% of cases, even in patients with other health conditions like diabetes or kidney disease.

Before this breakthrough, patients needed either a lumbar puncture (where doctors insert a needle into the spine) or expensive PET brain scans to confirm Alzheimer's. Both options kept many people from getting diagnosed early, when treatments work best.

Researchers at Washington University School of Medicine in St. Louis developed the technology, which was then refined by C2N Diagnostics. The test measures two key proteins using mass spectrometry and produces results scored as negative, likely positive, or positive for Alzheimer's.

The timing matters because scientists know Alzheimer's starts damaging the brain years before memory problems appear. Catching it early gives patients more treatment options and better outcomes.

The Ripple Effect

Just over a year ago, no FDA-cleared blood tests existed for Alzheimer's. Now there are three, showing how research investment is finally paying off for patients and families.

About 7.4 million Americans aged 65 and older live with Alzheimer's, plus another 200,000 younger people with early-onset disease. This test won't be used for routine checkups, but it gives doctors a powerful new tool for people already experiencing cognitive changes.

The breakthrough also opens doors for better clinical trials and personalized treatment approaches. When patients get diagnosed earlier through simple blood tests, researchers can study which treatments work best at different disease stages.

Faster, easier diagnosis means people worried about memory loss can get answers without invasive procedures, and those who test positive can start treatment when it has the greatest chance of slowing the disease.